Gilead Launches New Study To Evaluate Lenacapavir In HIV Prevention As Part Of PURPOSE Program

(RTTNews) - Gilead Sciences, Inc. (GILD) Wednesday said it launched PURPOSE 5, the company's Phase 2 study to evaluate lenacapavir as long-acting HIV prevention option. https://www.nasdaq.com/articles/gilead-launches-new-study-to-evaluate-lenacapavir-in-hiv-prevention-as-part-of-purpose